Company news
Ernexa Therapeutics Inc. news in 2025
Ernexa Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
December 8, 2025
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
December 3, 2025
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
December 2, 2025
Ernexa Therapeutics to Present at Oxford Global’s Cell 2025
November 11, 2025
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials
November 10, 2025
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
November 6, 2025
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
October 1, 2025
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
September 29, 2025
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
September 17, 2025
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
September 10, 2025
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
July 9, 2025
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
June 25, 2025
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
June 24, 2025
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
June 10, 2025
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
May 28, 2025
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
May 14, 2025
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
May 8, 2025
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
April 29, 2025
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
April 22, 2025
Ernexa Therapeutics Closes New Funding Round
April 3, 2025
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
March 25, 2025
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
February 26, 2025
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
January 27, 2025
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
January 13, 2025
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
January 8, 2025
Decks in 2025
- Investor Presentation (December 2025)
Investor deck · 31 slides · Dec 11, 2025